News
Biomanufacturing for Advanced Therapies Training Program
The biomanufacturing sector for advanced therapies is experiencing rapid growth and an escalating demand for personnel with specialized skill sets compared to conventional biopharmaceutical manufacturing. To address this need, OBIO® and CATTI have partnered to deliver the Biomanufacturing for Advanced Therapies Training Program, including cell and gene therapy (CGT), funded by Upskill Canada [powered by Palette Skills] and the Government of Canada.
The program focuses on both conceptual and practical skills essential to the development and manufacturing of Advanced Therapy Medicinal Products (ATMPs), with a curriculum developed through extensive collaborations with companies in the sector developing CGTs and tailored to meet their specialized workforce needs.
The program:
-
Cell Culture and Aseptic Techniques Bootcamp: a one-week (~40 hrs), hands-on training course at CATTI’s Guelph facility (on-site) designed for participants to master key skills such as cell culture, aseptic techniques, and good documentation practices, with proficiency assessed by experienced trainers. Other locations may become available in Q2-Q3 of 2025 for the hands-on component of the training. Stay tuned!
-
Part-time courses completing the bootcamp: virtual training in advanced therapies Good Manufacturing Practice (GMP), Chemistry, manufacturing, and controls (CMC), Quality Assurance (QA), Intellectual Property (IP) and licensing, and professional skills
-
Based on a stackable credentialing approach
Participant eligibility:
To be eligible for this program, you must meet the following criteria:
-
Reside in Canada (applicable to participants across all provinces).
-
Be a Canadian citizen, permanent resident, or have a work permit valid for at least one year after the start of the program.
-
Have completed post-secondary education and not currently be enrolled as a full-time student. If enrolled, you must graduate before the start of the program.
-
Have a minimum of 3 years of work experience outside of high school and post-secondary studies (work experience can be outside of Canada, does not need to be 3 consecutive years, can include volunteering, and can be a combination of full- and part-time work).
-
If unemployed, you will have to create a profile on the OBIO® Job Board and Talent Network.
-
Have an interest in advancing your career or transitioning into a new position, after completing the program.
More info on this link
CATTI and the Cell and Gene Therapy Catapult to establish shared training standards for advanced therapies manufacturing
The Canadian Advanced Therapies Training Institute (CATTI) and the Cell and Gene Therapy Catapult (CGT Catapult) have developed an aligned training and assessment strategy for the advanced therapies manufacturing industry. The strategy is an important first step towards developing shared standards that will help the growing industry to access a skilled workforce.
The manufacturing of advanced therapies is carried out by highly trained personnel who are certified to work according to Good Manufacturing Practice (GMP) and in aseptic conditions. The training and assessment for these personnel currently varies around the world, making it more difficult for the workforce to relocate and for the industry to access global talent.
CATTI and the CGT Catapult entered into a collaboration in 2023 with the aim of increasing levels of standardisation in the training and assessment standards used in Canada and the UK. The organisations have since aligned training materials and programmes, and outlined a joint strategy that sets out the specific skills and competencies that should be assessed. This will result in a rigorous template that can be applied across all manufacturing training materials and at various skill levels.
Vanessa Laflamme, CEO of CATTI, stated, “This partnership marks a crucial step towards ensuring that our workforce is equipped with the highest level of expertise to meet industry demands. By setting these international standards, we aim to enhance the quality and safety of advanced therapies, ultimately benefiting patients worldwide.”
Matthew Durdy, chief executive at the CGT Catapult, added, “By sharing expertise and working with CATTI, a leading provider of training for the advanced therapies industry, we have a valuable opportunity to enhance and standardise the training available to organisations and individuals. This builds on the efforts of the CGT Catapult to date, and the investment we have made, alongside government, in developing a successful training programme for the UK workforce. Together, we aim to ensure that our growing global sector is supported by a highly skilled workforce equipped with the latest knowledge and skills.”
CATTI and bioMérieux Canada are joining forces to support the development of a qualified workforce in advanced therapies.
December 7, 2023 (Montreal, Canada) – CATTI and bioMérieux Canada are combining their respective strengths to enhance the training of the workforce in advanced therapies and the production of quality control solutions (for the pharmaceutical industries).
For more details follow the link
CATTI et bioMérieux Canada unissent leurs forces pour soutenir le développement d'une main-d'œuvre qualifiée en thérapies avancées.
7 décembre 2023 (Montréal, Canada) – CATTI et bioMérieux Canada unissent leurs forces respectives pour développer la formation de la main-d’œuvre en thérapies avancées et la production de fourniture de solutions de contrôle qualité (pour les industries pharmaceutiques).
Suivez le lien pour plus d’information
CATTI and Cell and Gene Therapy Catapult partner to establish international best practice standards in advanced therapies manufacturing training
October 12, 2023 (London, United Kingdoms), (Montreal, Canada) — The Canadian Advanced Therapies Training Institute (CATTI) and Cell and Gene Therapy Catapult (CGT Catapult) have entered into an agreement to advance regenerative medicine, including cell and gene therapy training locally and globally. Both institutions have agreed to the development of joint activities to address issues of mutual interest. The ultimate goal is to establish international best practice standards in advanced therapies manufacturing training.